跳转至内容
Merck
CN

R-018

Retigabine solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C16H18FN3O2
化学文摘社编号:
分子量:
303.33
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-835-2
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Retigabine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

InChI key

PCOBBVZJEWWZFR-UHFFFAOYSA-N

InChI

1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)

grade

certified reference material

form

liquid

feature

(Snap-N-Spike®)

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

General description

Retigabine, also known as ezogabine, is a new antiepileptic drug developed for treatment of partial seizures. The drug is marketed under the trade names Potiga in the US and Trobalt in the EU. This certified solution standard is suitable for use as starting material in calibrators and controls for LC/MS or GC/MS methods in clinical toxicology, forensic analysis, urine drug testing, pain prescription monitoring, or pharmaceutical research applications.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

FlameExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Flam. Liq. 2

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

42.8 °F - closed cup - Solvent

flash_point_c

6.0 °C - closed cup - Solvent

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Dawn Craig et al.
PharmacoEconomics, 31(2), 101-110 (2013-01-24)
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of retigabine (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of adults with partial-onset seizures in epilepsy, with and without
Piotr Czuczwar et al.
Pharmacological reports : PR, 62(2), 211-219 (2010-05-29)
Retigabine represents an antiepileptic drug possessing a completely different mechanism of action when compared to the existing classical and newer antiepileptic drugs. In the therapeutic range, retigabine enhances potassium currents, very likely via destabilization of a closed conformation or stabilization
Marrissa Martyn-St James et al.
Seizure, 21(9), 665-678 (2012-08-21)
Retigabine (RTG) is now approved in Europe and the US for the adjunctive treatment of partial-onset seizures in adults with epilepsy. To support submissions to EU reimbursement authorities, we explored its efficacy and tolerability relative to selected antiepileptic drugs (AEDs).
Michele Y Splinter
Clinical therapeutics, 34(9), 1845-1856 (2012-08-25)
Ezogabine, also known as retigabine, is a recently approved anticonvulsant medication with a novel mechanism of action. It activates low-threshold voltage-gated potassium channels, leading to hyperpolarization of the membrane potential, stabilization of the resting membrane potential, and suppression of repetitive
G Blackburn-Munro et al.
CNS drug reviews, 11(1), 1-20 (2005-05-04)
Retigabine [D23129; N-(2-amino-4-(4-fluorobenzylamino)-phenyl)carbamic acid ethyl ester] is an antiepileptic drug with a recently described novel mechanism of action that involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels. These channels (primarily K(V)7.2/7.3) enable generation of the M-current, a subthreshold

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持